Steroid hormones interrelationships in the metabolic syndrome: An introduction to the ponderostat hypothesis

Hormones

Volumn 11, Issue 3, 2012, Pages 272-289

  Alemany, Marià ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

Author keywords

Androgens; Estrogens; Glucocorticoids; Metabolic syndrome; Obesity; Ponderostat

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; AMPHETAMINE; ANDROGEN; DEXFENFLURAMINE; DOPAMINE; ENDORPHIN; EPHEDRINE; ESTROGEN; ESTRONE; FLUOXETINE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; INSULIN; MELANOCORTIN; OREXIN; PHENTERMINE; PRASTERONE; RIMONABANT; SERTRALINE; SEX HORMONE BINDING GLOBULIN; SIBUTRAMINE; TESTOSTERONE;

ANDROID OBESITY; APPETITE; BEHAVIOR CHANGE; BODY FAT DISTRIBUTION; DISEASE ASSOCIATION; DISORDERS OF STEROID METABOLISM; ENDOCRINE FUNCTION; ENERGY METABOLISM; FOOD INTAKE; GYNOID OBESITY; HORMONE ACTION; HORMONE METABOLISM; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOANDROGENISM; HYPOPHYSIS FUNCTION; HYPOTHALAMUS FUNCTION; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; IMMUNOMODULATION; INFLAMMATION; INSULIN RESISTANCE; LIPID STORAGE; MENOPAUSE; METABOLIC SYNDROME X; NEUROMODULATION; OBESITY; PATHOGENESIS; PATHOPHYSIOLOGY; PONDEROSTAT SYSTEM; REVIEW; SEROTONINERGIC SYSTEM; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SLEEP PATTERN; WHITE ADIPOSE TISSUE;

EID: 84864846822     PISSN: 11093099     EISSN: None     Source Type: Journal    
DOI: 10.14310/horm.2002.1356     Document Type: Review

References (287)

1. Vague J, 1956 The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 4: 20-34.
2. Hattori K, Numata N, Ikoma M, Matsuzaka A, Danielson RR, 1991 Sex differences in the distribution of subcutaneous and internal fat. Hum Biol 63: 53-63.
3. Starcke S, Vollmer G, 2006 Is there an estrogenic component in the metabolic syndrome. Genes Nutr 1: 177-188.
4. Yanase T, Fan WQ, Kyoya K, Min L, Takayanagi R, Kato S, Nawata H, 2008 Androgens and metabolic syndrome: Lessons from androgen receptor knock out (ARKO) mice. J Steroid Biochem Mol Biol 109: 254-257.
5. Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES, 2004 Relationship to insulin resistance of the Adult Treatment Panel II diagnostic criteria for identification of the metabolic syndrome. Diabetes 53: 1195-1200.
6. R eaven G, 2004 The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metabol Clin North Am 33: 283-303.
7. Maury E, Brichard SM, 2010 Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 314: 1-16.
8. Vidal H, 2003 Obésité et inflammation: les adipocytokines. Ann Endocrinol 64: S40-S44.
9. O'Rourke RW, 2009 Molecular mechanisms of obesity and diabetes: At the intersection of weight tregulation, inflammation, and glucose homeostasis. World J Surg 33: 2007-2013.
10. Miranda PJ, DeFronzo RA, Califf RM, Guyton JR, 2005 Metabolic syndrome: Definition, pathophysiology, and mechanisms. Am Heart J 149: 33-45.
11. Potenza MV, Mechanick JI, 2009 The metabolic syndrome: Definition, global impact, and pathophysiology. Nutr Clin Pract 24: 560-577.
12. Kaplan NM, 1989 The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 149: 1514-1520.
13. Bosello O, Zamboni M, 2000 Visceral obesity and metabolic syndrome. Obes Rev 1: 47-56.
14. Hayes L, Pearce MS, Firbank MJ, Walker M, Taylor R, Unwin NC, 2010 Do obese but metabolically normal women differ in intra-abdominal fat and physical activity levels from those with the expected metabolic abnormalities? A cross-sectional study. BMC Publ Hlth 10: 723.
15. Messier V, Karelis AD, Prud'homme D, Primeau V, Brochu M, Rabasa-Lhoret R, 2010 Identifying metabolically healthy but obese individuals in sedentary postmenopausal women. Obesity 18: 911-917.
16. Pascot A, Després JP, Lemieux I, et al, 2000 Contribution of visceral obesity to the deterioration of the metabolic risk profile in men with impaired glucose tolerance. Diabetologia 43: 1126-1135.
17. Stefan N, Kantartzis K, Machann J, et al, 2008 Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 168: 1609-1616.
18. E sposito K, Nicoletti G, Giugliano D, 2002 Obesity, cytokines and endothelial dysfunction: A link for the raised cardiovascular risk associated with visceral obesity. J Endocrinol Invest 25: 646-649.
19. Karelis AD, 2008 Metabolically healthy but obese individuals. Lancet 372: 1281-1283.
20. Marques-Vidal P, Pécoud A, Hayoz D, et al, 2010 Normal weight obesity: Relationship with lipids, glycaemic status, liver enzymes and inflammation. Nutr Metab Cardiovasc Dis 20: 669-675.
21. R omero-Corral A, Somers VK, Sierra-Johnson J, et al, 2010 Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality. Eur Heart J 31: 737-746.
22. E rlingsson S, Herard S, Leinhard OD, et al, 2009 Men develop more intraabdominal obesity and signs of the metabolic syndrome after hyperalimentation than women. Metabolism 58: 995-1001.
23. Catalano KJ, Stefanovski D, Bergman RN, 2010 Critical role of the mesenteric depot versus other intra-abdominal adipose depots in the development of insulin resistance in young rats. Diabetes 59: 1416-1423.
24. Chapados N, Collin P, Imbeault P, Corriveau P, Lavoie JM, 2008 Exercise training decreases in vitro stimulated lipolysis in a visceral (mesenteric) but not in the retroperitoneal fat depot of high-fat-fed rats. Br J Nutr 100: 518-525.
25. E bal E, Cavalié H, Michaux O, Lac G, 2008 Visceral fat and total body fat mass correlate differently with hormones in rat. Pathol Biol 56: 283-285.
26. Marin P, Björntorp P, 1993 Endocrine metabolic pattern and adipose tissue distribution. Horm Res 39: 81-85.
27. Gower BA, Muñoz J, Desmond R, Hilario-Hailey T, Jiao XX, 2006 Changes in intra-abdominal fat in early postmenopausal women: Effecs of hormone use. Obesity 14: 1046-1055.
28. Bryzgalova G, Lundholm L, Portwood N, et al, 2008 Mechanisms of antidiabetogenic and body weightlowering effects of estrogen in high-fat diet-fed mice. Am J Physiol 295: E904-E912.
29. Pelleymounter MA, Baker MB, McCaleb M, 1999 Does estradiol mediate leptin's effects on adiposity and body weight? Am J Physiol 276: E955-E963.
30. Björntorp P, 1987 Classification of obese patients and complications related to the distribution of surplus fat. Am J Clin Nutr 45: 1120-1125.
31. Vague J, 1947 La différenciation sexuelle facteur déterminant des formes de l'obésité. Presse Med 55: 339-340.
32. Trémollieres FA, Pouilles JM, Ribot CA, 1996 Relative influence of age and menopause on total and regional body composition changes in postmenopausal women. Am J Obstet Gynecol 175: 1594-1600.
33. Casson PR, Elkind-Hirsch KE, Buster JE, Homsby PJ, Carson SA, Snabes MC, 1997 Effect of postmenopausal estrogen replacement on circulating androgens. Obstet Gynecol 90: 995-998.
34. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C, 2004 Androgens and bone. Endocr Rev 25: 389-425.
35. Tracz MJ, Sideras K, Bolona ER, et al, Clinical review: Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab 91: 2011-2016.
36. Valsamakis G, Chetty R, Anwar A, Banerjee AK, Barnett A, Kumar S, 2004 Association of simple anthropometric measures of obesity with visceral fat and the metabolic syndrome in male Caucasian and Indo-Asian subjects. Diabet Med 21: 1339-1345.
37. R ebuffé-Scrive M, Marin P, Björntorp P, 1991 Effect of testosterone on abdominal adipose tissue in men. Int J Obesity 15: 791-795.
38. Blouin K, Richard C, Bélanger C, et al, 2003 Local androgen inactivation in abdominal visceral adipose tissue. J Clin Endocrinol Metab 88: 5944-5950.
39. Blouin K, Richard C, Brochu G, et al, 2006 Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men. J Endocrinol 191: 637-649.
40. Kapoor D, Goodwin E, Channer KS, Jones TH, 2006 Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 154: 899-906.
41. Gould DC, Amoroso P, Kirby RS, 2006 Hypoandrogenmetabolic syndrome: A significant issue for men's health. BJU Int 98: 494-496.
42. Hamilton EJ, Gianatti E, Strauss BJ, et al, 2011 Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol 74: 377-383.
43. A kishita M, Fukai S, Hashimoto M, et al, 2010 Association of low testosterone with metabolic syndrome and its components in middle-aged Japanese men. Hypertens Res 33: 587-591.
44. Tchernof A, Labrie F, 2004 Dehydroepiandrosterone, obesity and cardiovascular disease risk: a review of human studies. Eur J Endocrinol 151: 1-14.
45. Giagulli VA, Kaufman JM, Vermeulen A, 1994 Pathogenesis of the Decreased Androgen Levels in Obese Men. J Clin Endocrinol Metab 79: 997-1000.
46. L ima N, Cavaliere H, Knobel M, Halpern A, Medeiros-Neto G, 2000 Decreased androgen levels in massively obese men may be associated with impaired fuction of the gonadostat. Int J Obesity 24: 1433-1437.
47. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB, 2006 Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 91: 843-850.
48. L i CY, Giles WH, Ford ES, Liu SM, Li BY, 2010 Association of testosterone and sex hormone-binding globulin with metabolic syndrome and insulin resistance in men. Diabet Care 33: 1618-1624.
49. Matsumoto AM, Bremner WJ, 2004 Serum testosterone assays. Accuracy matters. J Clin Endocrinol Metab 89: 520-524.
50. L ea OA, Støa KF, 1972 The binding of testosterone to different serum proteins: A comparative study. Journal of Steroid Biochemistry 3: 409-419.
51. Blouin K, Després JP, Couillard C, et al, 2005 Contribution of age and declining androgen levels to features of the metabolic syndrome in men. Metabolism 54: 1034-1040.
52. Cleland WH, Simpson ER, Mendelson CR, 1985 Effects of aging and obesity on aromatase activity of human adipose cells. J Clin Endocrinol Metab 60: 174-177.
53. Brind J, Strain G, Miller L, Zumoff B, Vogelman J, Orentreich N, 1990 Obese men have elevated plasma levels of estrone sulfate. Int J Obesity 14: 483-486.
54. Cohen PG, 1999 The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt-a major factor in the genesis of morbid obesity. Med Hypoth 52: 49-51.
55. Zumoff B, Miller LK, Strain GW, 2003 Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone. Metabolism 52: 1126-1128.
56. Schaller GB 1964 The year of the gorilla, Chicago: University of Chicago Press.
57. Gesta S, Bluher M, Yamamoto Y, et al, 2006 Evidence for a role of developmental genes in the origin of obesity and body fat distribution. Proc Nat Acad Sci USA 103: 6676-6681.
58. Shen W, Punyanitya M, Silva AM, et al, 2009 Sexual dimorphism of adipose tissue distribution across the lifespan: a cross-sectional whole-body magnetic resonance imaging study. Nutr Metab 6: 17.
59. Cowell CT, Briody J, Lloyd-Jones S, Smith C, Moore B, Howman-Giles R, 1997 Fat distribution in children and adolescents-the influence of sex and hormones. Horm Res 48: 93-100.
60. L abayen I, Moreno LA, Blay MG, et al, 2006 Early programming of body composition and fat distribution in adolescents. J Nutr 136: 147-152.
61. Perfetto F, Tarquini R, Cornélissen G, et al, 2004 Circadian phase difference of leptin in android versus gynoid obesity. Peptides 25: 1297-1306.
62. A hima RS, Dushay J, Flier SN, Prabakaran D, Flier JS, 1997 Leptin accelerates the onset of puberty in normal female mice. J Clin Invest 99: 391-395.
63. R ing LE, Zeltser LM, 2010 Disruption of hypothalamic leptin signaling in mice leads to early-onset obesity, but physiological adaptations in mature animals stabilize adiposity levels. J Clin Invest 120: 2931-2941.
64. Goodarzi MO, Azziz R, 2006 Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome. Best Pract Res Clin Endocr Metab 20: 193-205.
65. Gilling-Smith C, Willis DS, Beard RW, Franks S, 1994 Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab 79: 1158-1165.
66. Ducluzeau PH, Laville M, Vidal H, Pugeat M, 2001 Résistance à l'insuline et syndrome des ovaires polykystiques. Diabete Metabol 27: S7-S12.
67. Orio F, Palomba S, Cascella T, et al, 2003 Adiponectin levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88: 2619-2623.
68. Tarkun I, Arslan BC, Cantürk Z, Türemen E, Sahin T, Duman C, 2004 Endothelial dysfunction in young women with polycystic ovary syndrome: Relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 89: 5592-5596.
69. Meyer C, McGrath BP, Teede HJ, 2005 Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab 90: 5711-5716.
70. Pasquali R, Gambineri A, Pagotto U, 2006 The impact of obesity on reproduction in women with polycystic ovary syndrome. Br J Obstet Gynaecol 113: 1148-1159.
71. A ttaoua R, El Mkadem SA, Radian S, et al, 2008 FTO gene associated to metabolic syndrome in women with polycystic ovary syndrome. Biochem Biophys Res Commun 373: 230-234.
72. Vignesh JP, Mohan V, 2007 Polycystic ovary syndrome: A component of metabolic syndrome? J Postgrad Med 53: 128-134.
73. Kumar A, Woods KS, Bartolucci AA, Azziz R, 2005 Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol 62: 644-649.
74. Gilling-Smith C, Story H, Rogenrs V, Franks S, 1997 Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol 47: 93-99.
75. Goodarzi MO, Erickson S, Port SC, Jennrich RI, Korenman SG, 2003 Relative impact of insulin resistance and obesity on cardiovascular risk factors in polycystic ovary syndrome. Metabolism 52: 713-719.
76. Moll E, van der Veen F, van Wely M, 2007 The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Up 13: 527-537.
77. E ssah PA, Wickham EP, Nestler JE, 2007 The metabolic syndrome in polycystic ovary syndrome. Clin Obstet Gynecol 50: 205-225.
78. L ankarani M, Valizadeh N, Heshmat R, Peimani M, Sohrabvand F, 2009 Evaluation of insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome. Gynecol Endocrinol 25: 504-507.
79. Bhattacharya SM, 2010 Prevalence of metabolic syndrome in women with polycystic ovary syndrome, using two proposed definitions. Gynecol Endocrinol 26: 516-520.
80. Gould DC, Kirby RS, Amoroso P, 2007 Hypoandrogen-metabolic syndrome: a potentially common and underdiagnosed condition in men. Int J Clin Pract 61: 341-344.
81. Kaplan SA, Meehan AG, Shah A, 2006 The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men? J Urol 176: 1524-1527.
82. Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, Lenzi A, Forti G, Mannucci E, Maggi M, 2011 Testosterone and metabolic syndrome: A meta-analysis study. J Sex Med 8: 272-283.
83. Howard JM, 2007 Common factor of cancer and the metabolic syndrome may be low DHEA. Ann Epidemiol 17: 270.
84. Charlton M, Angulo P, Chalasani N, et al, 2008 Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatol 47: 484-492.
85. Korhonen S, Hippeläinen M, Vanhala M, Heinonen S, Niskanen L, 2003 The androgenic sex hormone profile is an essential feature of metabolic syndrome in premenopausal women: a controlled community-based study. Fertil Steril 79: 1327-1334.
86. R odriguez A, Muller DC, Metter EJ, et al, 2007 Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 92: 3568-3572.
87. Corbould A, 2008 Effects of androgens on insulin action in women: is androgen excess a component of female metabolic syndrome? Diab Metab Res Rev 24: 520-532.
88. A lexandre C, 2005 Androgens and bone metabolism. Joint Bone Spine 72: 202-206.
89. Mauras N, 2006 Growth hormone and testosterone: Effects on whole body metabolism and skeletal muscle in adolescence. Horm Res 66: 42-48.
90. Ophoff J, van Proeyen K, Callewaert F, et al, 2009 Androgen signaling in myocytes contributes to the maintenance of muscle mass and fiber type regulation but not to muscle strength or fatigue. Endocrinology 150: 3558-3566.
91. R uzzin J, Wagman AS, Jensen J, 2005 Glucocorticoidinduced insulin resistance in skeletal muscles: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor. Diabetologia 48: 2119-2130.
92. Natsui K, Tanaka K, Suda M, et al, 2006 High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporosis Int 17: 105-108.
93. Schakman O, Gilson H, Kalista S, Thissen JP, 2009 Mechanisms of muscle atrophy induced by glucocorticoids. Horm Res 72: 36-41.
94. Shamlian T, Cole MG, 2006 Androgen treatment of depressive symptoms in older men: A systematic review of feasibility and effectiveness. Can J Psychiat 51: 295-299.
95. Zarrouf FA, Artz S, Griffith J, Sirbu C, Kommor M, 2009 Testosterone and depression: Systematic review and meta-analysis. J Psychiatr Pract 15: 289-305.
96. Giltay EJ, Tishova YA, Mskhalaya GJ, Gooren LJG, Saad F, Kalinchenko SY, 2010 Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med 7: 2572-2582.
97. Kalynchuk LE, Gregus A, Boudreau D, Perrot-Sinal TS, 2004 Corticosterone increases depression-like behavior, with some effects on predator odor-induced defensive behavior, in male and female rats. Behav Neurosci 118: 1365-1377.
98. Burke HM, Davis MC, Otte C, Mohr DC, 2005 Depression and cortisol responses to psychological stress: A meta-analysis. Psychoneuroendocrinology 30: 846-856.
99. Zhao Y, Ma R, Shen J, Su H, Xing DM, Du LJ, 2008 A mouse model of depression induced by repeated corticosterone injections. Eur J Pharmacol 581: 113-120.
100. Killinger DW, Strutt BJ, Roncari DA, Khalil MW, 1995 Estrone formation from dehydroepiandrosterone in cultured human breast adipose stromal cells. J Steroid Biochem Mol Biol 52: 195-201.
101. Schwarz HP, 1990 Conversion of dehydroepiandrosterones sulfate (DHEA-S) to estrogens and testosterone in young nonpregnant women. Horm Metabol Res 22: 309-310.
102. Favre J, Gao J, Henry JP, et al, 2010 Endothelial estrogen receptor a plays an essential role in the coronary and myocardial protective effects of estradiol in ischemia/reperfusion. Arterioscler Thromb Vasc Biol 30: 2562-2567.
103. Xu Y, Armstrong SJ, Arenas IA, Pehowich DJ, Davidge ST, 2004 Cardioprotection by chronic estrogen or superoxide dismutase mimetic treatment in the aged female rat. Am J Physiol 287: H165-H171.
104. R iant E, Waget A, Cogo H, Arnal JF, Burcelin R, Gourdy P, 2009 Estrogens protect against high-fat diet-induced insulin resistance and glucose intolerance in mice. Endocrinology 150: 2109-2117.
105. Windler EE, Kovanen PT, Chao YS, Brown MS, Havel RJ, Goldstein JL, 1980 The estradiol-stimulated lipoprotein receptor of rat liver. A binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E. J Biol Chem 255: 10464-10471.
106. Hay RV, Pottenger LA, Reingold AL, Getz GS, Wissler RW, 1971 Degradation of I125-labelled serum low density lipoprotein in normal and estrogen-treated male rats. Biochem Biophys Res Commun 44: 1471-1477.
107. Simpkins JW, Dykens JA, 2008 Mitochondrial mechanisms of estrogen neuroprotection. Brain Res Rev 57: 421-430.
108. L ebesgue D, Chevaleyre V, Zukin RS, Etgen AM, 2009 Estradiol rescues neurons from global ischemia-induced cell death: Multiple cellular pathways of neuroprotection. Steroids 74: 555-561.
109. Guo XM, Lu X, Ren HM, Levin ER, Kassab GS, 2006 Estrogen modulates the mechanical homeostasis of mouse arterial vessels through nitric oxide. Am J Physiol 290: H1788-H1797.
110. Stirone C, Duckles SP, Krause DN, Procaccio V, 2005 Estrogen increases mitochondrial efficiency and reduces oxidative stress in cerebral blood vessels. Mol Pharmacol 68: 959-965.
111. Villa P, Sagnella F, Perri C, et al, 2008 Low-and standard-estrogen dosage in oral therapy: dose-dependent effects on insulin and lipid metabolism in healthy postmenopausal women. Climacteric 11:498-508.
112. Yoon M, 2009 The role of PPARa in lipid metabolism and obesity: Focusing on the effects of estrogen on PPARa actions. Pharmacol Res 60: 151-159.
113. A l-Azzawi F, Palacios S, 2009 Hormonal changes during menopause. Maturitas 63: 135-137.
114. Sarrel PM, 2002 Androgen deficiency: menopause and estrogen-related factors. Fertil Steril 77: 63-67.
115. Bachmann GA, 2002 The hypoandrogenic woman: pathophysiologic overview. Fertil Steril 77: 72-76.
116. Tang V, Torregrosa C, Remesar X, Alemany M, 2001 Dietary oleoyl-estrone affects the growth rate of young rats. Eur J Nutr 40: 17-22.
117. van den Belt K, Berckmans P, Vangenechten C, Verheyen R, Witters H, 2004 Comparative study on the in vitro in vivo estrogenic potencies of 17 beta-estradiol, estrone, 17 alpha-ethynylestradiol and nonylphenol. Aquat Toxicol 66: 183-195.
118. Schlindler AE, Ebert A, Friedrich E, 1972 Conversion of androstenedione to estrone by human fat tissue. J Clin Endocrinol Metab 35: 627-630.
119. R emesar X, Fernández-López JA, Savall P, et al, 2002 Effect of oral oleoyl-estrone on adipose tissue composition in male rats. Int J Obesity 26: 1092-1102.
120. E steve M, Virgili J, Aguilar H, et al, 1999 Leptin enhances the synthesis of oleoyl-estrone from estrone in white adipose tissue. Eur J Nutr 38: 99-104.
121. Vilà R, Cabot C, Villarreal L, Monegal A, et al, 2011 Oleoyl-estrone is a precursor of an estrone-derived ponderostat signal. J Steroid Biochem Mol Biol 124: 99-111.
122. L evin BE, Patterson CM, 2005 Exercising the obese brain: Resetting the defended body weight. Endocrinology 146: 1674-1675.
123. Grasa MD, Cabot C, Esteve M, et al, 2001 Daily oral oleoyl-estrone gavage induces a dose-dependent loss of fat in Wistar rats. Obes Res 9: 202-209.
124. Buscemi S, Caimi G, Verga S, 1996 Resting metabolic rate and postabsorptive substrate oxidation in morbidly obese subjects before and after massive weight loss. Int J Obesity 20: 41-46.
125. Cottam DR, Mattar SG, Barinas-Mitchell E, et al, 2004 The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: Implications and effects of weight loss. Obes Surg 14: 589-600.
126. Solá E, Jover A, López-Ruiz A, et al, 2009 Parameters of inflammation in morbid obesity: lack of effect of moderate weight loss. Obes Surg 19: 571-576.
127. L evin BE, Dunn-Meynell AA, 2002 Defense of body weight depends on dietary composition and palatability in rats with diet-induced obesity. Am J Physiol 282: R46-R54.
128. Weigensberg MJ, Toledo-Corral CM, Goran MI, 2008 Association between the metabolic syndrome and serum cortisol in overweight Latino youth. J Clin Endocrinol Metab 93: 1372-1378.
129. A nagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP, 2009 The pathogenetic role of cortisol in the metabolic syndrome: A hypothesis. J Clin Endocrinol Metab 94: 2692-2701.
130. Vogelzangs N, Beekman ATF, Dik MG, et al, 2009 Latelife depression, cortisol, and the metabolic syndrome. Am J Geriat Psychiat 17: 716-721.
131. van Steensel B, Jenster G, Damm K, Brinkmann AO, van Driel R, 1995 Domains of the human androgen receptor and glucocorticoid receptor involved in binding to the nuclear matrix. J Cell Biochem 57: 465-478.
132. Pasquali R, Vicennati V, Gambineri A, Pagotto U, 2008 Sex-dependent role of glucocorticoids and androgens in the pathophysiology of human obesity. Int J Obesity 32: 1764-1779.
133. Cheng MY, Sun G, Jin M, Zhao H, Steinberg GK, Sapolsky RM, 2009 Blocking glucocorticoid and enhancing estrogenic genomic signaling protects against cerebral ischemia. J Cereb Blood Flow Metab 29: 130-136.
134. Weiser MJ, Handa RJ, 2009 Estrogen impairs glucocorticoid dependent negative feedback on the hypothalamicpituitary-adrenal axis via estrogen receptor alpha within the hypothalamus. Neuroscince 159: 883-895.
135. Grasa MM, Serrano M, Fernández-López JA, Alemany M, 2007 Corticosterone inhibits the lipid-mobilizing effects of oleoyl-estrone in adrenalectomized rats. Endocrinology 148: 4056-4063.
136. Wolf G, 2002 Glucocorticoids in adipocytes stimulate visceral obesity. Nutr Rev 60: 148-151.
137. Wang M, 2005 The role of glucocorticoid action in the pathophysiology of the metabolic syndrome. Nutr Metab 2: 3.
138. Macfarlane DP, Forbes S, Walker BR, 2008 Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J Endocrinol 197: 189-204.
139. Napolitano A, Voice MW, Edwards CRW, Seckl JR, Chapman KE, 1998 11b-hydroxysteroid dehydrogenase 1 in adipocytes: Expression is differentiation-dependent and hormonally regulated. J Steroid Biochem Mol Biol 64: 251-260.
140. Tomlinson JW, Stewart PM, 2002 The functional consequences of 11b-hydroxysteroid dehydrogenase expression in adipose tissue. Horm Metabol Res 34: 746-751.
141. L ee MJ, Fried SK, Mundt SS, Wang Y, Sullivan S, Stefanni A, Daugherty BL, Hermanowski-Vosatka A, 2008 Depot-specific regulation of the conversion of cortisone to cortisol in human adipose tissue. Obesity 16: 1178-1185.
142. Stimson RH, Andersson J, Andrew R, et al, 2009 Cortisol release from adipose tissue by 11b-Hydroxysteroid Dehydrogenase type 1 in humans. Diabetes 58: 46-53.
143. Müller J, 1995 Aldosterone: The minority hormone of the adrenal cortex. Steroids 60: 2-9.
144. Hornsby PJ, 1995 Biosynthesis of DHEAS by the human adrenal cortex and its age-related decline. Ann NY Acad Sci 774: 29-46.
145. Havelock JC, Auchus RJ, Rainey WE, 2004 The rise in adrenal androgen biosynthesis: Adrenarche. Semin Reprod Med 22: 337-347.
146. R eynolds RM, Walker BR, 2003 Human insulin resistance: the role of glucocorticoids. Diabet Obes Metabol 5: 5-12.
147. A sensio C, Muzzin P, Rohner-Jeanrenaud F, 2004 Role of glucocorticoids in the physiopathology of excessive fat deposition and insulin resistance. Int J Obesity 28: S45-S52.
148. Zakrzewska KE, Cusin I, Sainsbury A, Rohner-Jeanrenaud F, Jeanrenaud B, 1997 Glucocorticoids as counterregulatory hormones of leptin-Toward an understanding of leptin resistance. Diabetes 46: 717-719.
149. Ray DW, 1996 Molecular mechanisms of glucocorticoid resistance. J Endocrinol 149: 1-5.
150. Ray PD, Foster DO, Lardy HA, 1964 Mode of action of glucocorticoids. I. Stimulation of gluconeogenesis independent of synthesis de novo of enzymes. J Biol Chem 239: 3396-3400.
151. May RC, Bailey JL, Mitch WE, Masud T, England BK, 1996 Glucocorticoids and acidosis stimulate protein and amino acid catabolism in vivo. Kidney Int 49: 679-683.
152. Tauchmanovà L, Pivonello R, di Somma C, Rossi R, de Martino MC, Camera L, Klain M, Salvatore M, Lombardi G, Colao A, 2006 Bone demineralization and vertebral fractures in endogenous cortisol excess: Role of disease etiology and gonadal status. J Clin Endocrinol Metab 91: 1779-1784.
153. Franchimont D, 2004 Overview of the actions of glucocorticoids on the immune response. A good model to characterize new pathways of immunosuppression for new treatment strategies. Ann NY Acad Sci 1024: 124-137.
154. Kirschbaum C, Prüssner JC, Stone AA, et al, 1995 Persistent high cortisol responses to repeated psychological stress in a subpopulation of healthy men. Psychosomat Med 57: 468-474.
155. Duclos M, Gouarne C, Bonnemaison D, 2003 Acute and chronic effects of exercise on tissue sensitivity to glucocorticoids. J Appl Physiol 94: 869-875.
156. Jensen J, Riis BJ, Strøm V, Nilas L, Christiansen C, 1987 Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol 156: 66-71.
157. Wortsman J, Frank S, Cryer PE, 1984 Adrenomedullary response to maximal stress in humans. Am J Med 77: 779-784.
158. Sutter-Dub MT, 2002 Rapid non-genomic and genomic responses to progestogens, estrogens, and glucocorticoids in the endocrine pancreatic B cell, the adipocyte and other cell types. Steroids 67: 77-93.
159. Kochakian CD, 1975 Definition of androgens and protein anabolic steroids. Pharmacol Ther B 1: 149-177.
160. Pasquali R, Vicennati V, Cacciari M, Pagotto U, 2006 The hypothalamic-pituitary-adrenal axis activity in obesity and the metabolic syndrome. Ann NY Acad Sci 1083: 111-128.
161. Chrousos GP, 2000 The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes. Int J Obesity 24: Suppl 2: 50-55.
162. R osmond R, 2005 Role of stress in the pathogenesis of the metabolic syndrome. Psychoneuroendocrinol 30: 1-10.
163. Hautanen A, Räikkönen K, Adlerkreutz H, 1997 Associations between pituitary-adrenocortical function and abdominal obesity, hyperinsulinaemia and dyslipidaemia in normotensive males. J Intern Med 241: 451-461.
164. L ivingstone DEW, Jones GC, Smith K, et al, 2000 Understanding the role of glucocorticoids in obesity: Tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 141: 560-563.
165. Wang MH, 2006 Tissue-specific glucocorticoid excess in the metabolic syndrome: 11b-HSD1 as a therapeutic target. Drug Develop Res 67: 567-569.
166. Grasa MM, Cabot C, Fernández-López JA, Remesar X, Alemany M, 2001 Modulation of corticosterone availability to white adipose tissue of lean and obese Zucker rats by corticosteroid-binding globulin. Horm Metabol Res 33: 407-411.
167. Barat P, Duclos M, Gatta B, Roger P, Mormede P, Moisan MP, 2005 Corticosteroid binding globulin gene polymorphism influences cortisol driven fat distribution in obese women. Obes Res 13: 1485-1490.
168. Bledsoe RK, Montana VG, Stanley TB, et al, 2002 Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110: 93-105.
169. E vans RM, 1988 The steroid and thyroid hormone receptor superfamily. Science 240: 889-895.
170. Chen SY, Wang J, Yu GQ, Liu WH, Pearce D, 1997 Androgen and glucocorticoid receptor heterodimer formation. A possible mechanism for mutual inhibition of transcriptional activity. J Biol Chem 272:14087-14092.
171. Mitra R, Sapolsky RM, 2010 Expression of chimeric estrogen-glucocorticoid-receptor in the amygdala reduces anxiety. Brain Res 1342: 33-38.
172. Mackem S, Baumann CT, Hager GL, 2001 A glucocorticoid/retinoic acid receptor chimera that displays cytoplasmic/nuclear translocation in response to retinoic acid. A real time sensing assay for nuclear receptor ligands. J Biol Chem 276: 45501-45504.
173. Genaro G, Franci CR, 2010 Cortisol influence on testicular testosterone secretion in domestic cat: An in vitro study. Pesq Vet Bras 30:887-890.
174. Dong Q, Salva A, Sottas CM, Niu EM, Holmes M, Hardy MR, 2004 Rapid glucocorticoid mediation of suppressed testosterone biosynthesis in male mice subjected to immobilization stress. J Androl 25: 973-981.
175. MacAdams MR, White RH, Chipps BE, 1986 Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Int Med 104: 648-651.
176. L abrie F, Bélanger A, Simard J, Luu-The V, Labrie C, 1995 DHEA and peripheral androgen and estrogen formation: intracrinology. Ann NY Acad Sci 774: 16-28.
177. A postolova G, Schweizer RAS, Balazs Z, Kostadinova RM, Odermatt A, 2005 Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue. Am J Physiol 288: E957-E964.
178. Browne ES, Wright BE, Porter JR, Svec F, 1992 Dehydroepiandrosterone. Antiglucocorticoid action in mice. Am J Med Sci 303: 366-371.
179. Gong H, Jarzynka MJ, Cole TJ, et al, 2008 Glucocorticoids antagonize estrogens by glucocorticoid receptormediated activation of estrogen sulfotransferase. Cancer Res 68: 7386-7393.
180. Weiser MJ, Foradori CD, Handa RJ, 2010 Estrogen receptor beta activation prevents glucocorticoid receptor-dependent effects of the central nucleus of the amygdala on behavior and neuroendocrine function. Brain Res 1336: 78-88.
181. Simoncini T, Maffei S, Basta G, et al, 2000 Estrogens and glucocorticoids inhibit endothelial vascular cell adhesion molecule-1 expression by different transcriptional mechanisms. Circul Res 87: 19-25.
182. da Silva JP, 1999 Sex hormones and glucocorticoids: Interactions with the immune system. Ann NY Acad Sci 876: 102-118.
183. Sheffield-Moore M, 2000 Androgens and the control of skeletal muscle protein synthesis. Ann Med 32: 181-186.
184. Isozaki Y, Mitch WE, England BK, Price SR, 1996 Protein degradation and increased mRNAs encoding proteins of the ubiquitin-proteasome proteolytic pathway in BC3H1 myocytes require an interaction between glucocorticoids and acidification. Proc Nat Acad Sci USA 93: 1967-1971.
185. Burt MG, Gibney J, Ho KKY, 2007 Protein metabolism in glucocorticoid excess: study in Cushing's syndrome and the effect of treatment. Am J Physiol 292: E1426-E1432.
186. Goldstein RE, Rossetti L, Palmer BA, et al, 2002 Effects of fasting and glucocorticoids on hepatic gluconeogenesis assessed using two independent methods in vivo. Am J Physiol 283: E946-E957.
187. Monroe SE, Menon KMJ, 1977 Changes in reproductive hormone secretion during the climacteric and postmenopausal periods. Clin Obstet Gynecol 20: 113-122.
188. Toth MJ, Tchernof A, Sites CK, Poehlman ET, 2000 Effect of menopausal status on body composition and abdominal fat distribution. Int J Obesity 24: 226-231.
189. Franklin RM, Ploutz-Snyder L, Kanaley JA, 2009 Longitudinal changes in abdominal fat distribution with menopause. Metabolism 58: 311-315.
190. Macdonald HM, New SA, Campbell MK, Reid DM, 2003 Longitudinal changes in weight in perimenopausal and early postmenopausal women: effects of dietary energy intake, energy expenditure, dietary calcium intake and hormone replacement therapy. Int J Obesity 27: 669-676.
191. Piché ME, Weisnagel SJ, Corneau L, Nadeau A, Bergeron J, Lemieux S, 2005 Contribution of abdominal vis ceral obesity and insulin resistance to the cardiovascular risk profile of postmenopausal women. Diabetes 54: 770-777.
192. Motivala AA, Rose PA, Kim HM, et al, 2008 Cardiovascular risk, obesity, and myocardial blood flow in postmenopausal women. J Nucl Cardiol 15: 510-517.
193. Mesch VR, Siseles NO, Maidana PN, et al, 2008 Androgens in relationship to cardiovascular risk factors in the menopausal transition. Climacteric 11: 509-517.
194. Korytkowski MT, Krug EI, Daly MA, DeRiso L, Wilson JW, Winters SJ, 2005 Does androgen excess contribute to the cardiovascular risk profile in postmenopausal women with type 2 diabetes? Metabolism 54: 1626-1631.
195. Bonomo SM, Rigamonti AE, Giunta M, Galimberti D, Guaita A, Gagliano MG, Müller EE, Cella SG, 2009 Menopausal transition: A possible risk factor for brain pathologic events. Neurobiol Aging 30: 71-80.
196. Kaye SA, Folsom AR, 1991 Is serum cortisol associated with body-fat distribution in postmenopausal women. Int J Obesity 15: 437-439.
197. Lindsay R, 1996 The menopause and osteoporosis. Obstet Gynecol 87:16S-19S.
198. Tenover JL, 1967 Testosterone and the aging male. J Androl 18: 103-106.
199. Delaporte E, 2008 Affections inflammatoires à médiation immunitaire et psoriasis. Ann Dermatol 135: Suppl 4: 269-274.
200. Karadag AS, Yavuz B, Ertugrul DT, et al, 2010 Is psoriasis a pre-atherosclerotic disease? Increased insulin resistance and impaired endothelial function in patients with psoriasis. Int J Dermatol 49: 642-646.
201. Reutrakul S, Hathout EH, Janner D, et al, 2004 Familial juvenile autoimmune hypothyroidism, pituitary enlargement, obesity, and insulin resistance. Thyroid 14: 311-319.
202. Mauras N, DelGiorno C, Kollman C, et al, 2010 Obesity without established comorbidities of the metabolic syndrome is associated with a proinflammatory and prothrombotic state, even before the onset of puberty in children. J Clin Endocrinol Metab 95: 1060-1068.
203. van Dijk SJ, Feskens EJM, Bos MB, et al, 2009 A saturated fatty acid-rich diet induces an obesity-linked proinflammatory gene expression profile in adipose tissue of subjects at risk of metabolic syndrome. Am J Clin Nutr 90: 1656-1664.
204. Fleming ME, Sales KM, Winslet MC, 2005 Diet and colorectal cancer: implications for the obese and devotees of the Atkins diet. Colorect Dis 7: 128-132.
205. Jaggers JR, Sui XM, Hooker P, et al, 2009 Metabolic syndrome and risk of cancer mortality in men. Eur J Cancer 45: 1831-1838.
206. Russo A, Autelitano M, Bisanti L, 2008 Metabolic syndrome and cancer risk. Eur J Cancer 44: 293-297.
207. Tubiash HS, 1951 The anaerogenic effect of nitrates and nitrites on Gram-negative enteric bacteria. Am J Publ Hlth 41: 833-838.
208. Dunca BB, Schmidt MI, 2001 Chronic activation of the innate immune system may underlie the metabolic syndrome. S Paulo Med J 119: 122-127.
209. Cani PD, Possemiers S, van de Wiele T, et al, 2009 Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58: 1091-1103.
210. Ley RE, Turnbaugh PJ, Klein S, Gordon JI, 2006 Human gut microbes associated with obesity. Nature 444: 1022-1023.
211. Najzer M, Seeley RJ, 2006 Obesity and gut flora. Nature 444: 1009-1010.
212. Delzenne NM, Cani PD, 2010 Nutritional modulation of gut microbiota in the context of obesity and insulin resistance: Potential interest of prebiotics. Int Dairy J 20: 277-280.
213. Manco M, Putignani L, Bottazzo GF, 2010 Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 31: 817-844.
214. Creely SJ, McTernan PG, Kusminski CM, et al, 2007 Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol 292: E740-E747.
215. Boivin MA, Ye D, Kennedy JC, Al-Sadi R, Shepela C, Ma TY, 2007 Mechanism of glucocorticoid regulation of the intestinal tight junction barrier. Am J Physiol 292: G590-G598.
216. Hales CN, Barker DJP, 2001 The thrifty phenotype hypothesis. Br Med Bull 60: 5-20.
217. Flodmark CE, 2002 Thrifty genotypes and phenotypes in the pathogenesis of early-onset obesity. Acta Paediatr 91: 737-738.
218. Sclafani A, Springer D, 1976 Dietary obesity in adult rats: Similarities to hypothalamic and human obesity syndromes. Physiol Behav 17: 461-471.
219. Prats E, Monfar M, Iglesias R, Castellà J, Alemany M, 1989 Energy intake of rats fed a cafeteria diet. Physiol Behav 45: 263-272.
220. R ogers PJ, 1985 Returning 'cafeteria-fed' rats to a chow diet: negative contrast and effects of obesity on feeding behaviour. Physiol Behav 35: 493-499.
221. Welle SL, Amatruda JM, Forbes GB, Lockwood DH, 1984 Resting metabolic rates of obese women after rapid weight loss. J Clin Endocrinol Metab 59: 113-122.
222. Brownell KD, Greenwood MRC, Stellar E, Shrager EE, 1986 The effects of repeated cycles of weight loss and regain in rats. Physiol Behav 38: 459-464.
223. Kirschner MA, Schneider G, Ertel NH, Gorman J, 1988 An 8-year experience with a very-low-calorie formula diet for control of major obesity. Int J Obesity 12: 69-80.
224. van Itallie TB, Kral JG, 1981 The dilemma of morbid obesity. J Am Med Assoc 246: 999-1003.
225. Dulloo AG, Girardier L, 1992 Influence of dietary composition on energy expenditure during recovery of body weight in the rat. Implications for catch up growth and obesity relapse. Metabolism 41: 1336-1342.
226. Bradley P, 1978 The ponderostat and a physiological model of obesity. Am J Clin Nutr 31: 1976-1978.
227. Dube MG, Xu B, Crowley WR, Kalra PS, Kalra SP, 1994 Evidence that neuropeptide Y is a physiological signal for normal food intake. Brain Res 646: 341-344.
228. Yang L, Scott KA, Hyun J, et al, 2009 Role of dorsomedial hypothalamic neuropeptide Y in modulating food intake and energy balance. J Neurosci 29: 179-190.
229. Benoit S, Schwartz M, Baskin D, Woods SC, Seeley RJ, 2000 CNS melanocortin system involvement in the regulation of food intake. Horm Behav 37: 299-305.
230. E llacott KLJ, Cone RD, 2006 The role of the central melanocortin system in the regulation of food intake and energy homeostasis: lessons from mouse models. Phil Trans Roy Soc Lond B 361: 1265-1274.
231. R affin-Sanson ML, de Keyzer Y, Bertagna X, 2003 Proopiomelanocortin, a polypeptide precursor with multiple functions: from physiology to pathological conditions. Eur J Endocrinol 149: 79-90.
232. Costin GE, Hearing VJ, 2007 Human skin pigmentation: melanocytes modulate skin color in response to stress. FASEB J 21: 976-994.
233. Schwartz RA, 1994 Acanthosis nigricans. J Am Acad Dermatol 31: 1-19.
234. Kahn CR, Flier JS, Bar RS, et al, 1976 The syndromes of insulin resistance and acanthosis nigricans. Insulinreceptor disorders in man. N Engl J Med 294: 739-745.
235. L ópez M, Lage R, Tung CL, et al, 2007 Orexin expression is regulated by alpha-melanocyte stimulating hormone. J Neuroendocrinol 19: 703-707.
236. R odgers RJ, Halford JCG, Nunes de Souza RL, et al, 2000 Dose-response effects of orexin-A on food intake and the behavioural satiety sequence in rats. Regul Peptides 96: 71-84.
237. Salin-Pascual RI, 2001 The role of the hypothalamic neuropeptides hypocretin/orexin in the sleep-wake cycle. Isr Med Assoc J 3: 144-146.
238. Bass J, Turek FW, 2005 Sleepless in America. A pathway to obesity and the metabolic syndrome? Arch Intern Med 165: 15-16.
239. Choi KM, Lee JS, Park HS, Baik SH, Choi DS, Kim SM, 2008 Relationship between sleep duration and the metabolic syndrome:Korean National Health Nutrition Survey 2001. Int J Obesity 32: 1091-1097.
240. Donga E, van Dijk M, van Dijk JG, et al, 2010 A single night of partial sleep deprivation induces insulin resistance in multiple metabolic pathways in healthy subjects. J Clin Endocrinol Metab 95: 2963-2968.
241. R osa Neto JC, Lira FS, Venancio DP, et al, 2010 Sleep deprivation affects inflammatory marker expression in adipose tissue. Lip Hlth Dis 9: 125.
242. Hasler G, Buysse DJ, Klaghofer R, et al, 2004 The association between short sleep duration and obesity in young adults: A 13-year prospective study. Sleep 27: 661-666.
243. Nielsen LS, Danielsen KV, Sørensen TIA, 2011 Short sleep duration as a possible cause of obesity: critical analysis of the epidemiological evidence. Obes Rev 12: 78-92.
244. R esta O, Barbaro MPF, Bonfitto P, et al, 2003 Low sleep quality and daytime sleepiness in obese patients without obstructive sleep apnoea syndrome. J Intern Med 253: 536-543.
245. Fukagawa K, Sakata T, Yoshimatsu H, Fujimoto K, Uchimura K, Asano C, 1992 Advance shift of feeding circadian rhythm induced by obesity progression in Zucker rats. Am J Physiol 263: R1169-R1175.
246. Dickmeis T, Lahiri K, Nica G, et al, 2007 Glucocorticoids play a key role in circadian cell cycle rhythms. PLoS Biol 5: 854-864.
247. Dallman MF, Viau VG, Bhatnagar S, Gomez F, Laugero K, Beli ME, 2011 Corticotropin-releasing factor, corticosteroids, stress, and sugar: energy balance, the brain and behavior. Hormones Brain and Behavior 1: 571-631.
248. E lmquist JK, Coppari R, Balthasar N, Ichinose M, Lowell BB, 2005 Identifying hypothalamic pathways controlling food intake, body weight, and glucose homeostasis. J Comp Neurol 493: 63-71.
249. L ópez M, Varela L, Vázquez MJ, et al, 2010 Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat Med 16: 1001-1008.
250. Handa RJ, Burgess LH, Kerr JE, O'Keefe JA, 1994 Gonadal steroid hormone receptors and sex differences in the hypothalamo-pituitary-adrenal axis. Horm Behav 28: 464-476.
251. Kiss A, Jezova D, Aguilera G, 1994 Activity of the hypothalamic-pituitary-adrenal axis and sympathoadrenal system during food and water deprivation in the rat. Brain Res 663: 84-92.
252. Yoshimatsu H, Niijima A, Oomura Y, Katafuchi T, 1988 Lateral and ventromedial hypothalamic influences on hepatic autonomic nerve activity in the rat. Brain Res Bull 21: 239-244.
253. A trens DM, Holmes LJ, Jirasek M, Siviy SM, Solowij N, 1987 Hypothalamic modulation of thermogenesis and energy substrate utilization. Brain Res Bull 18: 303-308.
254. Kuo JJ, Silva AA, Hall JE, 2003 Hypothalamic melanocortin receptors and chronic regulation of arterial pressure and renal function. Hypertension 41: 768-774.
255. Wise RA, 2006 Role of brain dopamine in food reward and reinforcement. Phil Trans Roy Soc Lond B 361: 1149-1158.
256. Meguid MM, Fetissov SO, Varma M, et al, 2000 Hypothalamic dopamine and serotonin in the regulation of food intake. Nutrition 16: 843-857.
257. Kelley AE, Baldo BA, Pratt WE, Will MJ, 2005 Corticostriatal-hypothalamic circuitry and food motivation: Integration of energy, action and reward. Physiol Behav 86: 773-795.
258. Grill HJ, 2006 Distributed neural control of energy balance: Contributions from hindbrain and hypothalamus. Obesity 14: Suppl 5: 216-221.
259. Cummings DE, Overduin J, 2007 Gastrointestinal regulation of food intake. J Clin Invest 117: 13-23.
260. Colombani AL, Carneiro L, Benani A, et al, 2009 Enhanced hypothalamic glucose sensing in obesity: Alteration of redox signaling. Diabetes 58: 2189-2197.
261. Horn EM, Waldrop TG, 1997 Oxygen-sensing neurons in the caudal hypothalamus and their role in cardiorespiratory control. Resp Physiol 110: 219-228.
262. Mason WT, 1980 Supraoptic neurones of rat hypothalamus are osmosensitive. Nature 287: 154-157.
263. R othwell NJ, Stock MJ, 1987 Effect of diet and fenfluramine on thermogenesis in the rat: Possible involvement of serotonergic mechanisms. Int J Obesity 11: 319-324.
264. Heal DJ, Cheetham SC, Prow MR, Martin KF, Buckett WR, 1998 A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weightmodifying agents. Br J Pharmacol 125: 301-308.
265. L evine LR, Rosenblatt S, Bosomworth J, 1987 Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. Int J Obesity 11: 185-190.
266. Nielsen JA, Chapin DS, Johnson JL, Torgersen LK, 1992 Sertraline, a serotonin uptake inhibitor, reduces food intake and body weight in lean rats and genetically obese mice. Am J Clin Nutr 55:Suppl 1: 185-188.
267. Yu S, Holsboer F, Almeida OFX, 2008 Neuronal actions of glucocorticoids: Focus on depression. J Steroid Biochem Mol Biol 108: 300-309.
268. Porter RJ, Gallagher P, Watson S, Young AH, 2004 Corticosteroid-serotonin interactions in depression: a review of the human evidence. Psychopharmacol 173: 1-17.
269. Gómez R, Navarro M, Ferrer B, et al, 2002 A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 22: 9612-9617.
270. Boyd ST, Fremming BA, 2005 Rimonabant-A selective CB1 antagonist. Ann Pharmacother 39: 684-690.
271. Caul WF, Jones JR, Barrett RJ, 1988 Amphetamine's effects on food consumption and body weight. The role of adaptive processes. Behav Neurosci 102: 441-450.
272. Bukowiecki L, Follea N, Jahjah L, 1982 Ephedrine, a potential slimming drug, directly stimulates thermogenesis in brown adipocytes via β-adrenoreceptors. Int J Obesity 6: 343-350.
273. Michel C, Cabanac M, 1999 Effects of dexamethasone on the body weight set point of rats. Physiol Behav 68: 145-150.
274. Messerli FH, Bell DSH, Fonseca V, et al, 2007 Body weight changes with beta-blocker use: Results from GEMINI. Am J Med 120: 610-615.
275. Patten SB, Williams JVA, Lavorato DH, Brown L, McLaren L, Eliasziw M, 2009 Major depression, antidepressant medication and the risk of obesity. Psychoter Psychosomat 78: 182-186.
276. Vanina Y, Podolskaya A, Sedky K, et al, 2002 Body weight changes associated with psychopharmacology. Psychiat Serv 53: 842-847.
277. Fornari A, Pedrazzi P, Lippi G, Picciotto MR, Zoli M, Zini I, 2007 Nicotine withdrawal increases body weight, neuropeptide Y and Agouti-related protein expression in the hypothalamus and decreases uncoupling protein-3 expression in the brown adipose tissue in high-fat fed mice. Neurosci Lett 411: 72-76.
278. Keck PE, McElroy SL, 2003 Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. J Clin Psychiat 64: 1426-1435.
279. Mussell MP, Mitchell JE, de Zwaan M, Crosby RD, Seim HC, Crow SJ, 1996 Clinical characteristics associated with binge eating in obese females: A descriptive study. Int J Obesity 20: 324-331.
280. Fandiño J, Moreira RO, Preissler C, et al, 2010 Impact of binge eating disorder in the psychopathological profile of obese women. Comprehens Psychiat 51: 110-114.
281. Fairburn CG, Cooper Z, Doll HA, Norman P, O'Connor M, 2000 The natural course of bulimia nervosa and binge eating disorder in young women. Arch Gen Psychiat 57: 659-665.
282. Boggiano MM, Artiga AI, Pritchett CE, Chandler-Laney PC, Smith ML, Eldridge AJ, 2007 High intake of palatable food predicts binge-eating independent of susceptibility to obesity: an animal model of lean vs obese binge-eating and obesity with and without binge-eating. Int J Obesity 31: 1357-1367.
283. Dallman MF, Pecoraro N, Akana SF, et al, 2003 Chronic stress and obesity: A new view of "comfort food". Proc Nat Acad Sci USA 100: 11696-11701.
284. Kandiah J, Yake M, Jones J, Meyer M, 2006 Stress influences appetite and comfort food preferences in college women. Nutr Res 26: 118-123.
285. Belsare PV, Watve MG, Ghaskadbi SS, Bhat DS, Yajnik CS, Jog M, 2010 Metabolic syndrome: Aggression control mechanisms gone out of control. Med Hypoth 74: 578-589.
286. A lemany M, 2011 The defense of adipose tissue against excess substrate-induced hyperthrophia: Immune system cell infiltration and arrested metabolic activity. J Clin Endocrinol Metab 96: 66-68.
287. A lemany M, 2012 Do the interactions between glucocorticoids and sex hormones regulate the development of the metabolic syndrome? Front Endocrinol 3: 27.